Division of Miraca Holdings Inc.
Latest From Fujirebio Inc.
Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer
The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.
Not all initial public offerings are taken up, even in the best of funding years. Of the 54 life sciences IPOs registered in 1997, 11 (20%) were withdrawn because of pricing issues or lack of interest.
The Japanese firm Fujirebio is to pay ¥9.8 billion ($112.9 million) for Innogenetics, a Belgian diagnostics and biologics operation acquired by Abbott as part of the US firm's broader purchase of Solvay Pharmaceuticals earlier this year.
Brief summaries of recent advances in device research and clinical trials, including a new study sugesting that treating post-PCI patients with vascular closure devices in combination with bivalirudin have substantially reduced bleeding rates, and a large study of postmeenopausal women indicated that tracking CA-125 may be an effective way to detect early-stage ovarian cancer.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Therapeutic Areas
- Infectious & Viral Diseases
- Pacific Rim
- Parent & Subsidiaries
- Miraca Holdings Inc.
- Senior Management
- Yoshihiro Ashihara, Pres. & CEO
- Contact Info
Phone: (81) 3-6279-0800
2-1-1 Nishishinjuku, Shinjuku-ku